These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 16619506)

  • 1. IgG isotype conversion of a novel human anti-carcinoembryonic antigen antibody to increase its biological activity.
    Huang J; Shibaguchi H; Zhao J; Luo N; Kuroki M; Kinugasa T; Hirose Y; Yamada H; Kuroki M
    Anticancer Res; 2006; 26(2A):1057-63. PubMed ID: 16619506
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Replacement of the constant region gene of a novel anti-CEA antibody and characterization of its biological activity].
    Huang J; Shibaguchi H; Masahide K
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2006 Sep; 22(5):650-3. PubMed ID: 16948917
    [TBL] [Abstract][Full Text] [Related]  

  • 3. cDNA cloning and sequencing of a novel monoclonal antibody to carcinoembryonic antigen and construction of a mouse/human chimeric antibody.
    Shibaguchi H; Arakawa F; Imakiire T; Kuroki M; Kuroki M
    Anticancer Res; 2003; 23(6a):4383-8. PubMed ID: 14666725
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor growth suppression by a mouse/human chimeric anti-CEA antibody and lymphokine-activated killer cells in vitro and in SCID mouse xenograft model.
    Senba T; Kuroki M; Arakawa F; Yamamoto T; Kuwahara M; Haruno M; Ikeda S; Matsuoka Y
    Anticancer Res; 1998; 18(1A):17-24. PubMed ID: 9568050
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Murine monoclonal IgG3 antibodies to human colorectal tumor-associated antigens: production and characterization of antibodies active in both antibody-dependent cellular cytotoxicity and complement-mediated cytolysis.
    Woodhouse CS; Morgan AC
    Cancer Res; 1989 May; 49(10):2766-72. PubMed ID: 2713860
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of GnTIII in a recombinant anti-CD20 CHO production cell line: Expression of antibodies with altered glycoforms leads to an increase in ADCC through higher affinity for FC gamma RIII.
    Davies J; Jiang L; Pan LZ; LaBarre MJ; Anderson D; Reff M
    Biotechnol Bioeng; 2001 Aug; 74(4):288-94. PubMed ID: 11410853
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recombinant human monoclonal igA antibody against CEA to recruit neutrophils to CEA-expressing cells.
    Zhao J; Kuroki M; Shibaguchi H; Wang L; Huo Q; Takami N; Tanaka T; Kinugasa T; Kuroki M
    Oncol Res; 2008; 17(5):217-22. PubMed ID: 18980018
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Carcinoembryonic antigen-immunoglobulin Fc fusion protein (CEA-Fc) for identification and activation of anti-CEA immunoglobulin-T-cell receptor-modified T cells, representative of a new class of Ig fusion proteins.
    Ma Q; DeMarte L; Wang Y; Stanners CP; Junghans RP
    Cancer Gene Ther; 2004 Apr; 11(4):297-306. PubMed ID: 15002034
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cloning and sequencing of variable region cDNAs of a novel human monoclonal antibody to carcinoembryonic antigen, and generation of a single chain variable fragmented antibody.
    Shibaguchi H; Kuroki M; Kuroki M; Badran A; Hachimine K; Kinugasa T
    Anticancer Res; 2004; 24(5C):3355-60. PubMed ID: 15515431
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting of LAK activity to CEA-expressing tumor cells with an anti-CEA scFv/IL-2 fusion protein.
    Liao S; Khare PD; Arakawa F; Kuroki M; Hirose Y; Fujimura S; Tomita Y; Kuroki M
    Anticancer Res; 2001; 21(3B):1673-80. PubMed ID: 11497246
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Binding activities and antitumor properties of a new mouse/human chimeric antibody specific for GD2 ganglioside antigen.
    Alvarez-Rueda N; Leprieur S; Clémenceau B; Supiot S; Sébille-Rivain V; Faivre-Chauvet A; Davodeau F; Paris F; Barbet J; Aubry J; Birklé S
    Clin Cancer Res; 2007 Sep; 13(18 Pt 2):5613s-5620s. PubMed ID: 17875797
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of biological activity among nonfucosylated therapeutic IgG1 antibodies with three different N-linked Fc oligosaccharides: the high-mannose, hybrid, and complex types.
    Kanda Y; Yamada T; Mori K; Okazaki A; Inoue M; Kitajima-Miyama K; Kuni-Kamochi R; Nakano R; Yano K; Kakita S; Shitara K; Satoh M
    Glycobiology; 2007 Jan; 17(1):104-18. PubMed ID: 17012310
    [TBL] [Abstract][Full Text] [Related]  

  • 13. IgG subclass-independent improvement of antibody-dependent cellular cytotoxicity by fucose removal from Asn297-linked oligosaccharides.
    Niwa R; Natsume A; Uehara A; Wakitani M; Iida S; Uchida K; Satoh M; Shitara K
    J Immunol Methods; 2005 Nov; 306(1-2):151-60. PubMed ID: 16219319
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fucose removal from complex-type oligosaccharide enhances the antibody-dependent cellular cytotoxicity of single-gene-encoded antibody comprising a single-chain antibody linked the antibody constant region.
    Natsume A; Wakitani M; Yamane-Ohnuki N; Shoji-Hosaka E; Niwa R; Uchida K; Satoh M; Shitara K
    J Immunol Methods; 2005 Nov; 306(1-2):93-103. PubMed ID: 16236307
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diabody-based recombinant formats of humanized IgG-like bispecific antibody with effective retargeting of lymphocytes to tumor cells.
    Asano R; Kawaguchi H; Watanabe Y; Nakanishi T; Umetsu M; Hayashi H; Katayose Y; Unno M; Kudo T; Kumagai I
    J Immunother; 2008 Oct; 31(8):752-61. PubMed ID: 18779744
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The novel chimeric anti-NCAM (neural cell adhesion molecule) antibody ch.MK1 displays antitumor activity in SCID mice but does not activate complement-dependent cytolysis (CDC).
    Klehr M; Koehl U; Mühlenhoff M; Tawadros S; Fischer T; Schomäcker K; Heuckmann JM; Bochennek K; Jensen M
    J Immunother; 2009 Jun; 32(5):442-51. PubMed ID: 19609236
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhancement of the antitumor effect on combination therapy of an anticancer drug and its antibody against carcinoembryonic antigen.
    Shibaguchi H; Tsuru H; Kuroki M; Kuroki M
    Chemotherapy; 2012; 58(2):110-7. PubMed ID: 22507917
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antigen binding and biological activities of engineered mutant chimeric antibodies with human tumor specificities.
    Gillies SD; Wesolowski JS
    Hum Antibodies Hybridomas; 1990; 1(1):47-54. PubMed ID: 2129419
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Engineered antibodies of IgG1/IgG3 mixed isotype with enhanced cytotoxic activities.
    Natsume A; In M; Takamura H; Nakagawa T; Shimizu Y; Kitajima K; Wakitani M; Ohta S; Satoh M; Shitara K; Niwa R
    Cancer Res; 2008 May; 68(10):3863-72. PubMed ID: 18483271
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Functional in vitro studies of recombinant human immunoglobulin G and immunoglobulin A anti-D.
    Nielsen LK; Green TH; Norderhaug L; Sandlie I; Dziegiel MH
    Transfusion; 2007 Feb; 47(2):306-15. PubMed ID: 17302778
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.